Search Medical Condition
Please enter condition
Please choose location from dropdown

Auburn, California Clinical Trials

A listing of Auburn, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (49) clinical trials

Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

PRIMARY OBJECTIVES: I. To compare event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant MK-3475 (pembrolizumab) with patients randomized to adjuvant MK-3475 (pembrolizumab). SECONDARY OBJECTIVES: I. To assess the frequency and severity of toxicities on each of the arms. II. To compare between arms overall survival (OS), ...

Phase

1.05 miles

Learn More »

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) associated with rucaparib in patients with genomic LOH high and/or deleterious BRCA1/2 mutations within: Cohort 1: Patients with squamous cell histology or mixed histology with a squamous component; Cohort 2: Patients with non-squamous histology ...

Phase

1.05 miles

Learn More »

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

PRIMARY OBJECTIVES: I. To compare overall survival between patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer randomized to ramucirumab and MK-3475 (pembrolizumab) versus standard of care (SoC). SECONDARY OBJECTIVES: I. To compare response rates between the arms, including complete response (CR) ...

Phase

1.05 miles

Learn More »

Palbociclib in Real World Practice

This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.

Phase N/A

6.04 miles

Learn More »

Obinutuzumab With or Without Umbralisib Lenalidomide or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

PRIMARY OBJECTIVES: I. To compare the complete response rate at 6 cycles after randomization as defined by centrally read positron emission tomography (PET)/computed tomography (CT) (integral biomarker) of 2 targeted therapeutic regimens (obinutuzumab + umbralisib [TGR-1202] or obinutuzumab + lenalidomide) with obinutuzumab + chemotherapy (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and ...

Phase

6.04 miles

Learn More »

Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine whether cabozantinib S-malate (cabozantinib) can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic neuroendocrine tumors (NET) whose disease has progressed after treatment with everolimus. II. To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients ...

Phase

6.04 miles

Learn More »

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

PRIMARY OBJECTIVES: I. To compare recurrence-free survival (RFS) between patients with renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone. SECONDARY OBJECTIVES: I. To evaluate for differences in recurrence-free survival associated with perioperative nivolumab compared to surgery alone ...

Phase

6.04 miles

Learn More »

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

PRIMARY OBJECTIVES: I. To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), ...

Phase

6.04 miles

Learn More »

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

PRIMARY OBJECTIVES: Screening component: I. To establish a National Clinical Trials Network (NCTN) mechanism for genomically screening large but homogeneous cancer populations and subsequently assigning and accruing simultaneously to a multi-sub-study ?Master Protocol.? II. To evaluate the screen success rate defined as the percentage of screened patients that register for ...

Phase

6.04 miles

Learn More »